Jacobs Levy Equity Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-26,670
Closed -$315K 1124
2017
Q3
$315K Buy
+26,670
New +$299K 0.01% 785
2016
Q3
Sell
-36,800
Closed -$404K 1217
2016
Q2
$404K Sell
36,800
-92,890
-72% -$1.04M 0.01% 814
2016
Q1
$1.42M Buy
+129,690
New +$1.64M 0.03% 489
2015
Q4
Sell
-23,213
Closed -$461K 919
2015
Q3
$461K Sell
23,213
-2,580
-10% -$59.1K 0.01% 591
2015
Q2
$424K Sell
25,793
-5,400
-17% -$93.6K 0.01% 596
2015
Q1
$485K Sell
31,193
-7,609
-20% -$118K 0.01% 583
2014
Q4
$554K Buy
+38,802
New +$410K 0.01% 592
2014
Q2
Sell
-101,156
Closed -$723K 987
2014
Q1
$723K Buy
101,156
+34,456
+52% +$295K 0.01% 608
2013
Q4
$627K Sell
66,700
-24,900
-27% -$178K 0.01% 669
2013
Q3
$572K Sell
91,600
-43,100
-32% -$269K 0.01% 655
2013
Q2
$886K Buy
+134,700
New +$1.07M 0.02% 597

Other funds holding SCMP

Jacobs Levy Equity Management's SCMP Position: Q4 2017 in Review

Jacobs Levy Equity Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2017, closing a stake of 26,670 shares — an estimated $315K sold.

Jacobs Levy Equity Management first reported a position in SCMP in Q2 2013 and held it in 11 quarters. The position peaked at $1.42M in Q1 2016. 188 funds tracked by Wall St. Rank hold SCMP as of Q4 2017.

  • Jacobs Levy Equity Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 26,670 Sucampo Pharmaceuticals, Inc. shares in Q4 2017, an estimated $315K.
  • Jacobs Levy Equity Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and held it in 11 quarters.
  • Jacobs Levy Equity Management's Sucampo Pharmaceuticals, Inc. position peaked at $1.42M in Q1 2016.
  • 188 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2017.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2017, filed 13 Feb 2018.